Literature DB >> 19269918

Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management.

Friedhelm Raue1, Karin Frank-Raue.   

Abstract

Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant tumour syndrome caused by germline activating mutations of the RET proto-oncogene. It has a strong penetrance of medullary thyroid carcinoma (MTC) and can be associated with bilateral pheochromocytoma and primary hyperparathyroidism (MEN2A) within a single patient or family. Based on the phenotype three distinct clinical forms have been described: (1) classical MEN2A, (2) MEN2B, an association of MTC, pheochromocytoma and mucosal neuroma and (3) familial MTC (FMTC), which is associated with a very low incidence of other endocrinopathies. Each variant of MEN2 results from a different RET gene mutation, with a good genotype-phenotype correlation with regard to aggressiveness of MTC, time of onset of MTC and the presence or absence of other endocrine tumours. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on a classification of RET mutations into three risk levels using the genotype-phenotype correlations. MEN2 provides a unique model for early prevention and cure of cancer and for stratified roles of mutation-based diagnosis of carriers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269918     DOI: 10.14310/horm.2002.1218

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  19 in total

1.  RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2.

Authors:  V Neocleous; N Skordis; G Portides; E Efstathiou; C Costi; N Ioannou; M Pantzaris; V Anastasiadou; C Deltas; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

2.  Single oligoarray-based detection of specific M918T mutation in RET oncogene in multiple endocrine neoplasia type 2B.

Authors:  R A Pacheco-Rivera; E Hernández-Zamora; B González-Yebra; K Beattie; R Maldonado-Rodríguez; J C Santiago-Hernández; M E Medrano-Ortiz de Zárate; M Salcedo
Journal:  Clin Exp Med       Date:  2011-01-21       Impact factor: 3.984

3.  [Multiple endocrine neoplasia type 2].

Authors:  S-Y Sheu; K W Schmid
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

Review 4.  [Molecular pathology of thyroid tumors].

Authors:  K W Schmid
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

Review 5.  Sporadic and familial medullary thyroid carcinoma: state of the art.

Authors:  Tricia A Moo-Young; Amber L Traugott; Jeffrey F Moley
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

6.  How to Assess the Clinical Relevance of Novel RET Missense Variants in the Absence of Functional Studies?

Authors:  Thomas Karrasch; Saskia M Herbst; Ute Hehr; Andreas Schmid; Andreas Schäffler
Journal:  Eur Thyroid J       Date:  2016-02-25

7.  RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma.

Authors:  Sisi Wang; Bo Wang; Chao Xie; Daoxiong Ye
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

Review 8.  A primer on the genetics of medullary thyroid cancer.

Authors:  V Larouche; A Akirov; C M Thomas; M K Krzyzanowska; S Ezzat
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

9.  Coexistence of Multiple Endocrine Neoplasia Type 2B and Chilaiditi Sign: A Case Report.

Authors:  Deniz Cetin; Mustafa Unübol; Aykut Soyder; Engin Güney; Adil Coşkun; Serdar Ozbaş; Alparslan Unsal; Muhan Erkuş
Journal:  Case Rep Endocrinol       Date:  2012-10-17

10.  Integrated DNA-based/biochemical screening for early diagnosis of multiple endocrine neoplasia type 2A (MEN2A).

Authors:  Qin Cui; Wen Wang; Zhenzhen Fu; Xin Shao; Zhihong Zhang; Mei Zhang; Xianxia Ju; Kunlin Wang; Jiawei Chen; Hongwen Zhou
Journal:  J Biomed Res       Date:  2013-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.